Researchers from KAUST, King Faisal Specialist Hospital, and collaborators have developed a new method to predict cardiometabolic disease risk in underrepresented ethnic populations using genetic information and public databases. The study focused on Arab communities and created a framework to determine polygenic scores for more accurate heart disease prediction. The framework was validated using records of over 5,000 Arab patients, demonstrating that genetic risk complements conventional risk factors. Why it matters: This research addresses a critical gap in genomic data for non-European populations, potentially leading to more effective and personalized healthcare strategies in the Arab world and beyond.
Researchers at Khalifa University have developed an AI system capable of predicting cardiovascular disease (CVD) risks up to 12 years in advance. The AI model uses data from the Framingham Heart Study to assess long-term CVD risk factors. It outperforms existing methods in predicting CVD incidence over extended periods. Why it matters: This advancement could significantly improve preventative healthcare strategies in the UAE and globally by enabling earlier interventions for individuals at high risk of heart disease.
MBZUAI alumnus Ikboljon Sobirov is using AI to develop new diagnostic tools for cardiovascular disease at the University of Oxford. His research focuses on building imaging biomarkers by integrating transcriptomic data with medical scans. The goal is to predict how a patient will respond to specific medications using only images. Why it matters: This work showcases the potential of AI and multi-modal data to personalize medicine and improve healthcare outcomes in the region and globally.
KAUST researchers have identified the gene 'CIROZ' as responsible for pediatric heart defects and misplacement of internal organs, working with institutes in Saudi Arabia and worldwide. The research examined samples from 16 patients from 10 families, including four from Saudi Arabia, revealing CIROZ's role in embryonic development symmetry. The findings provide insights into heritable diseases, which are more prevalent in Saudi Arabia. Why it matters: Identifying this gene allows for focused research on preventative strategies and curative therapies for congenital heart defects, particularly relevant in regions with higher rates of such diseases.
MBZUAI researchers are developing AI applications for malaria prevention in Indonesia using sensory data fusion and digital twins. Another MBZUAI team is using machine learning and computer vision to detect cardiovascular disease from CT scans in collaboration with the University of Oxford. AI-powered remote patient monitoring is also being explored for proactive interventions and chronic disease management. Why it matters: These projects demonstrate the potential of AI to address healthcare challenges in underserved communities and improve disease prevention and management in the region.
MBZUAI researchers led by Dr. Mohammad Yaqub are developing AI algorithms for real-time medical diagnoses, including tools for multiple sclerosis and congenital heart disease. The team developed ScanNav, an AI fetal anomaly assessment system licensed by GE Healthcare for Voluson SWIFT ultrasound machines. ScanNav assists doctors during anomaly scans after 20 weeks of gestation to check for conditions like heart issues and spina bifida. Why it matters: This research has the potential to significantly improve the speed and accuracy of medical diagnoses in the UAE and beyond, addressing critical gaps in healthcare.
Pong C Yuen from Hong Kong Baptist University will present a talk on remote photoplethysmography (rPPG) detection. The talk will review the development of rPPG detection, share recent research, and discuss future directions. rPPG is a technology for non-contact computer vision and healthcare applications like heart rate estimation. Why it matters: Advancements in rPPG could enable new remote patient monitoring and diagnostic tools in the region, reducing the need for physical contact.